吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察

The Clinical Observation of Gemcitabine Combined with Cisplatin Regimen for the Patients with Advanced Non-Small Cell Lung Cancer

目的 观察吉西他滨（GEM）联合顺铂（DDP）治疗晚期非小细胞肺癌的客观有效率和毒副反应。方法 全组28例非小细胞肺癌均有病理组织学或细胞学检查证实。应用GP方案：GEM800～1000 mg/m^2＋NS 100 mL静滴30 min，d1，8，15；DDP 30 mg/m^2＋NS 500 mL静滴，d3-5。28 d为1个周期。每例至少完成2个周期以上评价疗效。结果 28例均可评价疗效，客观有效率RR42.9%，中位生存期MST9.2个月。其中CR 2例，PR 10例，SD 9例，PD 7例。主要毒副反应是骨髓抑制和轻度胃肠道反应。结论 吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效较好，毒副反应可以耐受。

Objective To observe the response rate（RR） and toxic reaction of gemcitabine （GEM）combined with cisplatin （DDP）regimen in treatment of patients with advanced non-small cell lung cancer. Methods 28 cases（ NSCLC）were confirmed by pathology and diagnosed as advanced NSCLC. The patients were given GEM 800 - 1 000 mg/m^2 ＋ NS 100 mL ivdrip 30 min, d1.8.5 ; DDP 30 mg/m^2 ＋ NS 500 mL ivdrip d3-5. It was renewed twenty-eight days. Results The response rate（ RR） was 42.9%. 2 cases got CR, 10 PR, 9 SD, 7 PD. MST was 9.2 months. The main toxic reaction showed marrow restraint and slight gastrointestinal reaction. Conclusions Gemcitabine combined with cisplatin regimen in treatment of advanced NSCLC patients has a good response rate, slight toxic reaction and a good tolerance. It was worth using in clinical further.